William Fairey
CIK 1727275 · EVP, Chief Commercial Officer · last filed 2026-06-17
William Fairey is an EVP, Chief Commercial Officer who has filed 24 SEC Form 4 insider transactions across 6 companies since 2018. The most recent filing, for MIRM, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$352.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $247.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$247.9K
6
24
-$352.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MIRM | Director | 2,500 | $99.16 | $247.9K | -$155.1K | 7 | 2026-06-17 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | — | $27.00 | — | $0 | 4 | 2026-06-11 |
| RNTX | Director | — | $0.80 | — | $0 | 1 | 2025-07-23 |
| Rein Therapeutics, Inc. (ALRN) Delisted | Director | — | $2.11 | — | $0 | 3 | 2024-12-06 |
| MyoKardia, Inc. (MYOK) Delisted | See Remarks | 8,125 | — | — | -$197.2K | 3 | 2020-02-19 |
| CCXI | Chief Operating Officer | — | $16.64 | — | $0 | 1 | 2018-01-05 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-03-02 | ASND | Notice (144) | −1,800 | -$435.8K | EDGAR |
| 2025-10-02 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-07-23 | RNTX | Grant (A) | — | $0 | EDGAR |
| 2025-06-13 | MIRM | Sell (S) | −3,203 | -$155.1K | EDGAR |
| 2025-06-11 | MIRM | Notice (144) | −3,203 | -$155.1K | EDGAR |
| 2025-06-02 | MIRM | Mixed | +5,703 | $0 | EDGAR |
| 2025-03-04 | ASND | Notice (144) | −1,006 | -$153.0K | EDGAR |
| 2024-12-06 | Rein Therapeutics, Inc. (ALRN) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.